The U.S. Animal and Plant Health Inspection Service has approved Boehringer Ingelheim Vetmedica’s new vaccine, Ingelvac CircoFLEX, to protect swine against diseases caused by porcine circovirus type 2. 

According to Klaas Okkinga, marketing manager for BIVI, Ingelvac CircoFLEX is a single-dose, 1 ml vaccine that provides the highest level of efficacy and safety to pigs. “It’s highly effective in immunizing pigs as young as three weeks of age prior to exposure to PCV2, and provides long-lasting protection without the systemic irritation and tissue reactions some vaccines can cause.”

In addition, Ingelvac CircoFLEX has a short 21-day withdrawal period and positive pork quality assurance benefits that are important to producers, Okkinga adds. “It was thoroughly field tested and we are confident this vaccine will help producers more effectively prevent porcine circovirus associated disease.”

Ingelvac CircoFLEX will be available to producers in the first quarter of 2007.

For more information on new Ingelvac CircoFLEX vaccine for PCV2, as well as the diagnosis and management of porcine circovirus associated disease, contact Boehringer Ingelheim Vetmedica, at (800) 325-9167.

Source: Boehringer Ingelheim news release